About us
Gedea Biotech was started by a multidisciplinary team from Lund University. The broad competence of our employees is the basis for our success. Today, we are approaching clinical trials and a product launch. Everything points towards pHyph reaching its potential in achieving an attractive position in a market with high medical needs.Equality and sustainability are our core values which influence all areas of our work. We aim to contribute to a better world where antibiotics are never used unnecessarily and we will do what we can to combat microbial resistance. Since starting up in 2015, we have gratefully received several prizes making us even prouder of what we have achieved so far.
Watch the film about Gedea Biotech, the team and what we are striving for
Annette Säfholm
CEO
Annette has a PhD in Medicine from Lund University and holds a Master's degree in Medical Biology from Linköping University. She has long experience of project management and business development in both listed and unlisted companies also from the healthcare sector.
This email address is being protected from spambots. You need JavaScript enabled to view it.
+46 (0) 708 - 91 86 81
CEO
Annette has a PhD in Medicine from Lund University and holds a Master's degree in Medical Biology from Linköping University. She has long experience of project management and business development in both listed and unlisted companies also from the healthcare sector.
This email address is being protected from spambots. You need JavaScript enabled to view it.
+46 (0) 708 - 91 86 81
We are Gedea
Eva Norell
Marketing manager
Eva has a MSc from Linköping University and has broad experience in medical marketing and project management in the healthcare sector. She has held positions in communication, marketing and sales at Pfizer, Sanofi, Studentlitteratur and within the Swedish Medical Association.
This email address is being protected from spambots. You need JavaScript enabled to view it.
+46 (0) 709 - 36 04 20
Marketing manager
Eva has a MSc from Linköping University and has broad experience in medical marketing and project management in the healthcare sector. She has held positions in communication, marketing and sales at Pfizer, Sanofi, Studentlitteratur and within the Swedish Medical Association.
This email address is being protected from spambots. You need JavaScript enabled to view it.
+46 (0) 709 - 36 04 20
Mahnaz Basimfar
Global QA Director
Mahnaz has a B.Sc. in chemistry and 30 years of experience in both drugs and medical devices. Mahnaz has served as QC / QA Director in several companies and has been the Audit Leader at inspections of several external pharmaceutical and medical technology companies in Europe, China and the United States. Within Gedea, Mahnaz is responsible for the implementation and construction of the company's quality management system and for leading the company to registration according to the quality standard ISO 13485 for medical technology.
Global QA Director
Mahnaz has a B.Sc. in chemistry and 30 years of experience in both drugs and medical devices. Mahnaz has served as QC / QA Director in several companies and has been the Audit Leader at inspections of several external pharmaceutical and medical technology companies in Europe, China and the United States. Within Gedea, Mahnaz is responsible for the implementation and construction of the company's quality management system and for leading the company to registration according to the quality standard ISO 13485 for medical technology.
Olov Sterner
Co-founder, Chairman of the board
Olov is Professor of Organic Chemistry at Lund University. He has extensive experience in starting and running innovative life science companies. Olov is co-founder of and Chairman of De-NovaStella AB, Board member of PULS (Life Science Partners), Respiratorius AB, Gabather AB and Glactone AB.
Co-founder, Chairman of the board
Olov is Professor of Organic Chemistry at Lund University. He has extensive experience in starting and running innovative life science companies. Olov is co-founder of and Chairman of De-NovaStella AB, Board member of PULS (Life Science Partners), Respiratorius AB, Gabather AB and Glactone AB.
Helena Strevens
Co-founder, board member, medical officer
Helena has a PhD in medicine and a senior consultant in obstetrics and gynecology. As a medical officer, she is responsible for clinical trials and questions regarding the use of the product. Helena has many years of experience in treating vaginal infections and their complications in clinical work. She is also a partner in PULS (Partners for Development Investments in Life Science).
Co-founder, board member, medical officer
Helena has a PhD in medicine and a senior consultant in obstetrics and gynecology. As a medical officer, she is responsible for clinical trials and questions regarding the use of the product. Helena has many years of experience in treating vaginal infections and their complications in clinical work. She is also a partner in PULS (Partners for Development Investments in Life Science).
Sophie Manner
Co-founder
Sophie has a PhD in organic chemistry and works as a researcher at Lund University. She is responsible for laboratory research and formulation within Gedea. Sophie is also a partner in PULS (Partners for Development Investments in Life Science).
Co-founder
Sophie has a PhD in organic chemistry and works as a researcher at Lund University. She is responsible for laboratory research and formulation within Gedea. Sophie is also a partner in PULS (Partners for Development Investments in Life Science).
Ulf Ellervik
Co-founder, responsible for R&D and patents
Ulf is Professor of Bioorganic Chemistry at Lund University, as well as a founder and member of the board of Molecular Knowledge AB. He is also a partner of PULS (Partners for Development Investments in Life Science).
Co-founder, responsible for R&D and patents
Ulf is Professor of Bioorganic Chemistry at Lund University, as well as a founder and member of the board of Molecular Knowledge AB. He is also a partner of PULS (Partners for Development Investments in Life Science).
Björn Andersson
Board Member
Björn is a civil engineer, Industrial Engineering and Managemnt, and has long experience as an entrepreneur and business angel (nominated twice for "Connect Angel of the Year" of Connect Syd). He is a board member of several smaller companies, as well as Fast Track Capital AB, which finances the companies in Fast Track Malmö.
Board Member
Björn is a civil engineer, Industrial Engineering and Managemnt, and has long experience as an entrepreneur and business angel (nominated twice for "Connect Angel of the Year" of Connect Syd). He is a board member of several smaller companies, as well as Fast Track Capital AB, which finances the companies in Fast Track Malmö.
Kerstin Valinder Strinnholm
Board Member
Kerstin is journalist from the School of Journalism at the University of Gothenburg. She has 30 years of senior management experience in international pharmaceutical companies such as AstraZeneca and Nycomed / Takeda. She works as a business development advisor and as a director of Camurus AB (publ), Corline Biomedical AB (publ), Immunicum AB (publ) and Klifo A / S.
Board Member
Kerstin is journalist from the School of Journalism at the University of Gothenburg. She has 30 years of senior management experience in international pharmaceutical companies such as AstraZeneca and Nycomed / Takeda. She works as a business development advisor and as a director of Camurus AB (publ), Corline Biomedical AB (publ), Immunicum AB (publ) and Klifo A / S.
Mats Persson
Board member
Mats has over 30 years of experience in the marketing and licensing business in the global pharmaceutical industry. Most recently Mats worked for Astellas Pharma, where he has been the General Manager for the Nordic and Baltic countries for the past ten years. He has long experience from senior positions in Novo Nordisk, Pharmacia Corporation and Ferring International.
Board member
Mats has over 30 years of experience in the marketing and licensing business in the global pharmaceutical industry. Most recently Mats worked for Astellas Pharma, where he has been the General Manager for the Nordic and Baltic countries for the past ten years. He has long experience from senior positions in Novo Nordisk, Pharmacia Corporation and Ferring International.
Per Antonsson
Board member
Per has a PhD in Medical Science and holds a Bachelor's Degree in Analytical Chemistry and Biochemistry from Lund University. As Investment Manager at Almi Invest, Per has long experience of business development and investment in start-up companies, preferably in life science. He has had several roles in pharmaceutical and biotechnology companies. Per is currently a board member of two other start-up companies in life science.
Board member
Per has a PhD in Medical Science and holds a Bachelor's Degree in Analytical Chemistry and Biochemistry from Lund University. As Investment Manager at Almi Invest, Per has long experience of business development and investment in start-up companies, preferably in life science. He has had several roles in pharmaceutical and biotechnology companies. Per is currently a board member of two other start-up companies in life science.
Stina Gestrelius
Board Member
Stina has a PhD in applied biochemistry and has 40 years of experience in research, development, management and board work in Scandinavian life science companies. As an entrepreneur, Stina has worked with research, development, manufacturing and regulatory issues within Biora AB. Stina has also been Vice President of Medicon Valley Alliance and is a member of the Board of Hansa Medical AB (publ).
Board Member
Stina has a PhD in applied biochemistry and has 40 years of experience in research, development, management and board work in Scandinavian life science companies. As an entrepreneur, Stina has worked with research, development, manufacturing and regulatory issues within Biora AB. Stina has also been Vice President of Medicon Valley Alliance and is a member of the Board of Hansa Medical AB (publ).
AWARDS AND PRIZES
Venture CupGame Changer Maj 2017
Venture Cup
Crowd Awards September 2017
Future Innovation
March 2017
EIT Health Catapult third prize andThe Public´s award 2018
Grant from Horizon 2020
September 2019
